What is Tasigna used for?

Tasigna is one of a group of medicines called ‘tyrosine kinase inhibitors’ (TKIs), which are used used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML).1,2

Who can use Tasigna:

  • People who are newly diagnosed with Ph+ CML in the chronic phase1,2
  • People with Ph+ CML in the chronic or accelerated phase who didn’t respond to prior therapy (including imatinib▼) or had to discontinue due to side effects1,2

How Tasigna works

Tasigna works by targeting the BCR-ABL protein that is causing the bone marrow to make abnormal white blood cells – the leukaemia cells. By stopping the BCR-ABL protein from sending its signal, Tasigna may reduce the number of leukaemia cells and allow healthy blood cells to grow.1,2

More information
For more information about Tasigna please consult:

Summary of Product Characteristics (SmPC) for Tasigna 50 mg and 200 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Summary of Product Characteristics (SmPC) for Tasigna 150 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient Information Leaflet (PIL) for Tasigna 50 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient Information Leaflet (PIL) for Tasigna 200 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient Information Leaflet (PIL) for Tasigna 150 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Summary of Product Characteristics (SmPC) for Glivec (imatinib) 100 mg and 400 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient Information Leaflet (PIL) for Glivec 100 mg and 400 mg
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

CML, chronic myeloid leukaemia; Ph+, Philadelphia chromosome positive; TKI, tyrosine kinase inhibitor.

References

  1. Tasigna® (nilotinib 200 mg and 50 mg) Summary of Product Characteristics. 2019.
  2. Tasigna® (nilotinib 150 mg) Summary of Product Characteristics. 2019.

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

ONC20-C058 June 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.